Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis

Clinical Nephrology

Volumn 70, Issue 3, 2008, Pages 220-228

  Abe, M ^a   Okada, K ^a   Kikuchi, F ^b   Matsumoto, K ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yamato Hospital   (Japan)

Author keywords

Hemodialysis; Hypertension; Insulin resistance; Pioglitazone; Type 2 diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; PHOSPHATE BINDING AGENT; PIOGLITAZONE; RECOMBINANT ERYTHROPOIETIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; URICOSURIC AGENT; VITAMIN D;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPERVOLEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; LEG EDEMA; LIVER DYSFUNCTION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 52149083499     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70220     Document Type: Article

References (46)

1. Aronoff S, Rosenblatt S, Braithwaite S, Egen JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes. Diabetes Care. 2000; 23: 1605-1611.
2. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004; 43: 1-10.
3. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002; 53: 409-435.
4. Bernobich E, de Angelis L, Lerin C, Bellini G. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs. 2002; 62: 1295-1314.
5. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone; evidence for a direct vascular effect. J Clin Invest. 1995; 96: 354-360.
6. Cranberry MC, Schneider EF, Fonseca VA. The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy. 1998; 18: 973-987.
7. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with Type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003; 26: 2983-2989.
8. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C. Further insight on the hypoglycemic and nonhypoglycemic effects of troghtazone 400 or 600 mg/d. Effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism. 2005; 51: 44-51.
9. Harold JM, Pharm D, Nicole M, Allcock PD. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy. 2003; 23: 861-865.
10. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with Type 2 diabetes. Metabolism. 2002; 51: 314-317.
11. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-γ on progression of insulin resistance and cardiovascular disease. Am J Cardiol. 2003; 92: 3-9.
12. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension. 1996; 28: 219-223.
13. Kotchen TA, Zhang HY, Reddy S, Hoffmann RG. Effects of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol. 1996; 270: R660-666.
14. Krepinsky J, Ingram AJ, Clase C. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000; 35: 500-505.
15. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J Clin Endocrininol Metab. 2001; 86: 280-288.
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorγ (PPARγ). J Biol Chem. 1995; 270: 12953-12956.
17. Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis. 2003; 42: 774-780.
18. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA. Metabolic effects of troglitazone monotherapy in Type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128: 176-185.
19. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002; 62: 1463-1480.
20. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and Type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocrinol Pract. 2003; 9: 406-416.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 45: S1-S153.
22. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the AHA and ADA. Circulation. 2003; 108: 2941-2948.
23. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004; 27: 256-263.
24. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport E, Salzman A. Once- and twice- daily dosing with rosiglitazone improves glycemic control in patients with Type 2 diabetes. Diabetes Care. 2001; 24: 308-315.
25. Phillips SA, Ciaraldi TP, Kong AP, Bandurkala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003; 52: 667-674.
26. Picard F, Auwerx J. PPARγ and glucose homeostasis. Annu Rev Nutr. 2002; 22: 167-197.
27. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003; 26: 172-178.
28. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334: 374-381.
29. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001; 276: 37731-37734.
30. Sarafidis PA, Lasaridis AN. Actions of PPARγ agonists explaining a possible blood pressure lowering effect. Am J Hypertens. 2006; 19: 646-653.
31. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension. 2003; 42: 664-668.
32. Shinohara K, Shoiji T, Emoto M. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 1894-1900.
33. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE inhibitors improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension. 2002; 40: 329-334.
34. Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol. 1999; 84: 3-10.
35. Sone H, Ito H, Ohashi Y. Japan Diabetes Complication Study (JDCS) Group: Obesity and Type 2 diabetes in Japanese patients. Lancet. 2003; 361: 85.
36. Spiegelman BM. PPAR: Adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998; 47: 507-514.
37. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin treated patients with Type 2 diabetes mellitus. Troglitazone and Exogeneous Insulin Study Group. N Engl J Med. 1998; 338: 861-866.
38. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Fukukawa L, Asagami T, Hino T, Sato F, Otsuka Y. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 1994; 23: 450-455.
39. Verma S, Bhanot S, Arikawa E, Yao L, McNeill JH. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology. 1998; 56: 7-16.
40. Wakino S, Law RE, Hsueh WA. Vascular protective effects by activation of nuclear receptor PPAR-γ. J Diabetes Compl. 2002; 16: 46-49.
41. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPAR-γ in the control of lipid metabolism. J Lipid Res. 2002; 43: 177-186.
42. Wiecek A, Adamczak M, Chudek J. Adiponectin - an adipokine with unique metabolic properties. Nephrol Dial Transplant. 2007; 22: 981-988.
43. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARγs: from orphan receptors to drug discovery. J Med Chem. 2000; 43: 527-550.
44. Wolffenbuttel BHR, Gomist R, Squatrito S, Jones NP, Patwardhan RN. Additional of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2-diabetic patients. Diabet Med. 2000; 17: 40-47.
45. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CWK, Li PKT. Rosiglitazone reduces insulin requirement and C-reactive protein levels in Type 2-diabetic patients receiving peritoneal dialysis. Am J Kidney Dis. 2005; 46: 713-719.
46. Yu JG, Javorschi S, Hevener AL, Truszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and Type 2-diabetic subjects. Diabetes. 2002; 51: 2968-2974.